Luminal A and luminal B/HER2-negative tumours, characterised by strong hormone receptor expression and relatively low proliferation, generally exhibit more favourable long-term survival but lower breast and nodal pCR rates after NACT than HER2-enriched and triple-negative subtypes, which are more chemosensitive yet biologically aggressive [29,30,31]. Here, ERBB2 is linked to neoplasm.